# Fragment 176-191 + CJC-1295 + Ipamorelin

> The Fragment 176-191 + CJC-1295 + Ipamorelin blend is a three-peptide research formulation that combines HGH Fragment 176-191, a 16-residue C-terminal piece of human growth hormone, with CJC-1295 without DAC, a GHRH analogue, and ipamorelin, a ghrelin receptor agonist. It is supplier-defined, not an approved or standardized product, and the combination has not been studied.

Canonical: https://peptideproperties.com/compounds/fragment-176-191-cjc-1295-ipamorelin/

## Identity

- **Class:** Growth Hormone Secretagogues & GHRH Analogs

## Key facts

- Components: HGH Fragment 176-191, CJC-1295 without DAC (Mod GRF 1-29) and ipamorelin
- Classes: hGH C-terminal fragment plus a GHRH analogue and a GHS-R1a agonist
- Commonly listed as a 12 mg vial by total content; split not standardized
- Molecular weights: fragment 1799.1; CJC-1295 no DAC 3367.9; ipamorelin 711.9 g/mol
- The fragment is studied for metabolic effects, not for stimulating GH release
- No published study of the three-peptide combination found in the PubMed records reviewed
- None of the three components is FDA approved

## What Is the Fragment 176-191 + CJC-1295 + Ipamorelin Blend?

The Fragment 176-191 + CJC-1295 + Ipamorelin blend is a supplier-defined, three-peptide formulation that combines a C-terminal fragment of human growth hormone with two growth hormone secretagogues: CJC-1295 without DAC (Mod GRF 1-29) and ipamorelin. It is commonly listed as a 12 mg vial by total content, and the listings tracked here do not state a standard split among the three peptides.HGH Fragment 176-191 reproduces residues 176-191 of human growth hormone; synthetic C-terminal hGH peptides including this sequence were tested in rats as early as 1978[1]. CJC-1295 without DAC is a GHRH analogue, and ipamorelin is a pentapeptide described as the first selective growth hormone secretagogue[2].The blend name says only "CJC-1295". In this catalog it refers to the form without DAC; CJC-1295 with DAC is a distinct molecule carrying an albumin-binding lysine extension[3]. The combination is not an approved or standardized product.

## Components at a Glance

Two components act on pituitary receptors that control growth hormone release; the third is a growth hormone fragment studied for metabolic effects rather than GH release.ComponentClassPrimary target or mechanism studiedMolecular weight (g/mol)HGH Fragment 176-191Synthetic C-terminal fragment of human GH (16 residues)No receptor defined in the cited sources; studied for effects on glucose, insulin and fat metabolism in rodents[1][4]1799.1CJC-1295 without DAC (Mod GRF 1-29)GHRH analogue (29 residues, four substitutions)GRF (GHRH) receptor on the anterior pituitary, shown for hGRF(1-29) derivatives[3]3367.9IpamorelinGrowth hormone secretagogueGhrelin receptor (GHS-R1a) agonist[5]711.9Molecular weights are PubChem values (CIDs 16131230, 56841945 and 9831659).

## Why These Compounds Are Studied Together

CJC-1295 and ipamorelin act on two different receptors in the growth hormone axis, while Fragment 176-191 is studied for a separate, metabolic line of research. No study of this three-peptide combination was found, and no cited source tests the fragment alongside either secretagogue.
### The secretagogue pair
Ipamorelin releases GH through a GHRP-like receptor rather than the GHRH receptor, as shown by profiling with GHRP and GHRH antagonists[2]. In rats treated with ipamorelin for 15 days, the pituitary GH response to GHRH was unchanged[6]. A 2026 review reported that CJC-1295 combined with ipamorelin improved maximum tetanic tension in a mouse model of glucocorticoid-induced muscle loss, limited to animal work; the abstract does not state which CJC-1295 form was used[7].
### The fragment
The C-terminal hGH domain has been studied for direct effects on fat tissue. The closely related 177-191 analog AOD-9401 stimulated hormone-sensitive lipase and inhibited acetyl-CoA carboxylase in isolated rat adipose tissue, and reduced body weight gain in obese Zucker rats without inducing insulin resistance[4]. In normal rats, however, the 176-191 sequence itself produced a short-lived rise in blood glucose and a more sustained rise in plasma insulin[1]. These data come from rodents and concern the fragment alone.
### Why they appear together
The grouping reflects how these peptides are marketed more than any tested rationale. A 2026 review lists Frag 176-191, ipamorelin and CJC-1295 among peptides promoted for muscle growth and fat metabolism, and notes that most published studies do not examine the combined protocols common in bodybuilding[8].With three peptides and easily confused fragment names, researchers typically check HPLC and mass spectrometry certificates of analysis that confirm each sequence.

## Research Status

The Fragment 176-191 + CJC-1295 + Ipamorelin blend has no regulatory approval and is supplied for laboratory research use only. None of its three components is FDA approved, and a 2026 review notes the absence of regulatory approval for physique- or performance-related uses of GH-axis peptides[9].hGH 176-191 is among the prohibited peptides targeted by a 2026 doping-control detection workflow[10]. Forensic analyses of seized material have identified glycine-modified analogues of ipamorelin and modified GRF 1-29[11], and unregulated peptide products are often mislabeled or contaminated[8]. Naming adds confusion: the review cited above refers to the GH fragment as "AOD9604 (hGH 176-191)", although AOD-9604 is a modified 177-191 sequence[9].Evidence quality is low: rodent and in vitro data for the fragment, mainly animal data for ipamorelin, limited peer-reviewed data for CJC-1295 without DAC, and no published data on the combination.

## FAQ

**What is in the Fragment 176-191 + CJC-1295 + Ipamorelin blend?**
The blend contains three peptides: HGH Fragment 176-191, a 16-residue sequence from the C-terminus of human growth hormone; CJC-1295 without DAC, a substituted 29-residue GHRH analogue; and ipamorelin, a five-residue ghrelin receptor agonist. It is commonly listed as a 12 mg vial by total content, with no standardized ratio among the components.

**Is Fragment 176-191 a growth hormone secretagogue?**
No. Unlike CJC-1295 and ipamorelin, Fragment 176-191 is not studied as a stimulator of GH release. It is a piece of the growth hormone molecule itself, researched in rodents for effects on glucose, insulin and fat metabolism. Most lipolysis data come from the related 177-191 analog AOD-9401 rather than the 176-191 sequence.

**Is Fragment 176-191 the same as AOD-9604?**
No, though the names are often mixed up. Fragment 176-191 is hGH residues 176-191. AOD-9401 is the shorter 177-191 sequence, and AOD-9604 adds a tyrosine to that 177-191 sequence. Some reviews still label the GH fragment as "AOD9604 (hGH 176-191)", so the exact sequence should be checked in any source or product document.

**Has the Fragment 176-191 + CJC-1295 + Ipamorelin combination been studied?**
No study of this three-peptide combination was found in the PubMed records reviewed. A review reports one mouse study of CJC-1295 with ipamorelin, and separate rodent studies cover the hGH C-terminal fragment. No cited study gives the fragment together with either secretagogue, so effects of the combined formulation are unknown.

## References

1. Ng FM, Bornstein J. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. The American journal of physiology 1978. PMID: 645904
2. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European journal of endocrinology 1998. PMID: 9849822
3. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005. PMID: 15817669
4. Ng FM, Jiang WJ, Gianello R, et al. Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats. Journal of molecular endocrinology 2000. PMID: 11116208
5. Lu Z, Ngan MP, Liu JYH, et al. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. Physiology & behavior 2024. PMID: 39043357
6. Johansen PB, Nowak J, Skjaerbaek C, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 1999. PMID: 10373343
7. Mayfield CK, Bolia IK, Feingold CL, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American journal of sports medicine 2026. PMID: 41476424
8. Coutinho LFD, DE Oliveira Neves LF, Camilo RP. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. The Journal of sports medicine and physical fitness 2026. PMID: 41880199
9. Dominikowski A, Rękoś Z, Olejarz M, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Frontiers in endocrinology 2026. PMID: 42395176
10. Mazzarino M, Colpaert T, Deventer K, et al. Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices. The Analyst 2026. PMID: 42328738
11. Gajda PM, Holm NB, Hoej LJ, et al. Glycine-modified growth hormone secretagogues identified in seized doping material. Drug testing and analysis 2019. PMID: 30136411